Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2024 Status changed from not yet recruiting to recruiting.
14 Nov 2024 According to an Enlivex Therapeutics media release,trial currently plans to recruit six patients who have insufficiently responded to conventional therapies for psoriatic arthritis.
14 Nov 2024 According to an Enlivex Therapeutics media release, company announced the completion of the dosing and initial follow-up period for the first patient in its Phase I clinical trial evaluating the safety, tolerability and potential therapeutic effect of Allocetra™ following injection into an affected joint in patients with psoriatic arthritis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com